Ilya Pharma will present Poster with AMR data for ILP100 at US military medical partnering conference MHSRS August 26-29 August, Kissimmee, FL
"The Military Health System Research Symposium (MHSRS) is the Department of Defense's premier scientific meeting that focuses specifically on the unique medical needs of the Warfighter. This annual educational symposium draws approximately 4,000 attendees and provides a collaborative environment for military medical care providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Information Sciences, Military Infectious Diseases, and the Radiation Health Effects." Link to conference: https://www.mhsrs.net
Break out session: Improving Traumatic Wound Healing and recovery, poster session 3 Wednesday 28th August at 10.00-12.00 local time.
Abstract:
CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria
Lofton Tomenius, H1,2., Pang, Y2., Pallin, A2, Emelie Öhnstedt, E1,2, Kadekar, S2., Myktebekova, Z2., Jorvid, M2, Carram Lelham, N2., Fasth, A2., Vågesjö, E1,2., Riesbeck., K3., Roos, S5., Phillipson, M1,4
1, Uppsala University, Department of Medical Cell Biology, Division of Integrative Physiology, Box 571, Uppsala, Sweden
2, Ilya Pharma AB, Dag Hammarskjölds väg 30, 752 37 Uppsala, Sweden
3, Lund University, Clinical Microbiology, Laboratory Medicine; Clinical Microbiology, Department of Translational Medicine, Faculty of Medicine, Lund University, SE-20502 Malmö, Sweden
4, The Science for Life Laboratory, Uppsala University
5, Swedish University of Agricultural Sciences, Uppsala Biocentre, Department of Molecular Sciences, Box 7015, SE-750 07, Uppsala, Sweden
Aim: High antibiotic resistance in bacteria from Ukrainian war victims is reported1,2. ILP100 (emilimogene sigulatibac) is a topical drug candidate (Limosilactobacillus reuteri expressing the chemokine CXCL12), induces growth inhibition of wound bacteria at administration and accelerates wound healing3,4,5. Here, direct antimicrobial effects of ILP100 on multidrug-resistant bacteria (MDRs) are tested.
Methods: Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloacae and Klebsiella pneumoniae including isolates clinically resistant to cephalosporins and carbapenems1 and a Staphylococcus aureus(JE2)6 were used. Disk diffusion utilizing soft agar overlays inoculated with MDRs (1x104-1x106 CFU) on triplicate spots with spot-dropped ILP100 (High dose: 1x108, Low dose: 5x106 CFUs) were incubated for 24h, imaged and analyzed blinded. Co-culturing for 12h was performed in ILP100:MDR ratios of 10:1 and 100:1 with 12 MDRs, where killing effect was measured as bacterial reduction relative to its control by serial dilution and plating.
Results/Discussion: The inhibition zone induced by high dose ILP100 resulted in clearance for all MDR isolates in the range of 35-268mm2 and 40-299mm2 for MDRs at 1x106 and 1x104, respectively, whereas low dose ILP100 resulted in 41-98mm2 and 50-269mm2 respectively.
Co-culturing in the ratio of 100:1 resulted in elimination of all MDRs except for K. pneumoniae, which was reduced by 6 logs. Most MDRs exhibited detectable reduction already at 3h and were at 6h reduced by 1-3 logs at 100:1, whereas 10:1 showed effect only for two P. aeruginosa isolates (reduced 1-2 logs).
Conclusion: In addition to accelerating wound healing, ILP100 exerts direct antimicrobial effects on multi-drug resistance bacteria.
References: 1) Ljungqvist et al 2023, Lancet Infections Diseases, 2) McGann et al., 2023, CDC Emerging Infections Diseases, 3) Vågesjö et al., 2018, PNAS, 4) Öhnstedt et al., 2021, Pharmaceutics, 5) Öhnstedt et al., 2023, eClinicalMedicine Lancet Science Discovery, 6) Fey et al., 2013, ASM Journals.